Patients with moderate kidney disease (eGFR 3060) may use tirzepatide with standard monitoring
Incidences of other toxicities were comparable across the three treatment groups in DURATION-8 (exenatide plus dapagliflozin, exenatide alone, and dapagliflozin alone, respectively), including pancreatitis (1.3%, 0.4%, and 0%), volume depletion (1.3%, 0.4%, and 2.1%), gastrointestinal events (20.8%, 23.9%, and 16.3%), and genital infections (5.2%, 2.2%, and 7.7%) [36]
The compound tirzepatide dosage calculations remain identical regardless of the pharmacy that produced the vial, as long as the concentration matches
For many patients, these medications make it possible to control blood sugar levels without the need for additional medications, said Dr